-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Fosamprenavir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/226700-79-4.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 226700-79-4 |
| Description | Fosamprenavir, also called as GW433908, Lexiva and Telzir, is an oral prodrug of the protease inhibitor (PI) amprenavir. Combined with other antiretroviral agents, Fosamprenavir is indicated for the treatment of patients with HIV infection, particularly those who have not previously received antiretroviral therapy. |
Product Information
| Synonyms | [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; 3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester; fosamprenavir; 226700-81-8 (calcium) GW 433908; GW-433908; GW-908 |
| IUPAC Name | [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate |
| Molecular Weight | 585.62 |
| Molecular Formula | C25H36N3O9PS |
| Canonical SMILES | CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N |
| InChI | 1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1 |
| InChIKey | MLBVMOWEQCZNCC-OEMFJLHTSA-N |
| Purity | > 95% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : ≥ 100 mg/mL(170.76 mM) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution |
| Appearance | Off White solid |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 912 |
| Exact Mass | 585.19098791 |
| Index Of Refraction | 1.612 |
| PSA | 195.91000 |
| Target | HIV |
| XLogP3-AA | 1.8 |
